Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Oak Tree who wrote (2800)	2/4/2001 11:09:11 PM
From: Jibacoa	Read Replies (2) \| Respond to of 52153

<<Radiation can get PTCA to about 7% also. That would leave out the stent completely. So I remain pro-radiation.>> At the Am.Heart Ass.Scientific Sess.2000 in New Orleans,Paul Terstein,M.D. from SCRIPPS Clinic in La Jolla,CA., presented the findings of SCRIPS III registry concerning 500 patients from CA. and also including patients from Lenox Hill Hosp. in NY. These were patients who presented with in-stent restenosis, and after having PTCA or atherectomy to achieve less than 30% residual stenosis, the use of a new stent was strongly discouraged and gamma radiation with Ir-192 was administered to achieve a dose of 14 Gray at 2mms. from the source. The antiplatelet therapy consisted of clopidogrel (which was given for 6 months to patients that received no stent and for 12 months to those that received a new stent) They compared the results with the GAMMA-1 study in which 85% of patients received new stents.In that study the incidence of late target vessel thrombosis and of myocardial infarctions were significantly higher (more than double) than the group receiving no brachytherapy. In GAMMA-1 the anticoagulation therapy with ticlopidine was continued for only 8 weeks and none of the thrombotic events took place while the patients were still on the medication or even within 30 days after it was discontinued. The results of SCRIPPS III were much better than those obtained on GAMMA-1. The requirements for new stents were reduced from 85% in GM-1 to 23% in SC-III and there were no late thromboses. The incidence of MIs was less than 3% (about 1/2 of the % of the control group in GM-1 and 1/4 of the % of the group that received brachytherapy in GM-1) Bernard